Kenta Noda

Kenta Noda

Auto-generated profile, based on publicly available information

Kenta Noda

R&D Department, Nittobo Medical Co., Ltd., Koriyama, Japan

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 July 2014 in Neurology
Verified
Journal Article
Closed access
PDF file
SSSetsu Sawai
Setsu Sawai
MSMamoru Satoh
Mamoru Satoh
MMMasahiro Mori
Masahiro Mori
SMSonoko Misawa
Sonoko Misawa
KSKazuyuki Sogawa
Kazuyuki Sogawa
SKSatoshi Kuwabara
Satoshi Kuwabara
Objective: Previous histochemical studies in the demyelinating form of Guillain-Barré syndrome (GBS), acute inflammatory demyelinating polyneuropathy (AIDP), have shown complement deposition on the surface of Schwann cells, and therefore unknown epitopes would be present on the outer surface of Schwann cells. Methods: We used a proteomic-based approach to search for the target molecules of AIDP in the extracted proteins from schwannoma cells. Sera were obtained from 40 patients with GBS, 31 controls with inflammatory disease, and 46 normal controls. Results: We found that patients with AIDP after cytomegalovirus (CMV) infection have serum autoantibodies against membrane-organizing extension spike protein (moesin), which is expressed in the Schwann cell processes at the nodes of Ranvier and is crucial for myelination. Of the 40 patients with GBS, 6 had recent CMV infection and 5 of them (83%) had high levels of serum immunoglobulin G antibodies against moesin. The anti-moesin antibodies were found in none of the control subjects with disease including 5 with CMV infection but no neuropathy, and only 2 (4%) of the 46 normal control subjects. Immunocytochemistry showed that moesin was stained at the distal tips of schwannoma cells by sera from the patients with CMV-related AIDP but not by sera from controls. Conclusion: Moesin is a possible immunologic target molecule of pathogenic autoantibodies in patients with CMV-related AIDP. Classification of evidence: This study provides Class II evidence that levels of serum anti-moesin antibodies accurately distinguishes CMV-related AIDP from non–CMV-related AIDP (sensitivity 83%, specificity 93%).

4 February 2017 in Cancer Science
Verified
Journal Article
Open access
PDF file
MSMamoru Satoh
Mamoru Satoh
STShigetsugu Takano
Shigetsugu Takano
KSKazuyuki Sogawa
Kazuyuki Sogawa
KNKenta Noda
Kenta Noda
HYHideyuki Yoshitomi
Hideyuki Yoshitomi
FNFumio Nomura
Fumio Nomura
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies. To improve its outcome, reliable biomarkers are urgently needed. In this study, we aimed to elucidate the key molecules involved in PDAC progression using proteomics approaches. First, we undertook 2‐D electrophoresis to identify the proteins overexpressed in PDAC tissues. Following the analysis of agarose gel spots, cofilin‐1 was identified and verified as a candidate protein commonly upregulated in PDAC tissues. In immunohistochemistry, cofilin‐1 was strongly expressed in the cytoplasm of PDAC cells. Samples were divided into two groups based on the level of cofilin‐1 expression. The high expression group showed significantly higher incidence of hematogenous dissemination in relapsed patients than the low expression group (P = 0.0083). In in vitro experiments, knockdown of cofilin‐1 significantly decreased chemotaxis in PDAC cell lines. After we confirmed that cofilin‐1 was secreted from PDAC cells, we established a detection system for the immune‐complex of cofilin‐1 in sera. Using this system, we measured the IC levels of cofilin‐1 in sera and observed that the IC levels of cofilin‐1 in PDAC patients were higher than those in healthy volunteers and patients with pancreatitis (PDAC vs. healthy volunteers, P < 0.0001; PDAC vs. patients with pancreatitis, P < 0.026). Notably, the IC levels of cofilin‐1 showed a stepwise increase during PDAC progression (P = 0.0034), and high IC levels of cofilin‐1 indicated poor prognosis of patients after surgery (P = 0.039). These results suggest that the IC of cofilin‐1 in sera is a potentially attractive serum biomarker for the prognosis of PDAC.

12 July 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MGMegumi Goto
Megumi Goto
KCKenji Chamoto
Kenji Chamoto
KHKeiko Higuchi
Keiko Higuchi
SYSaya Yamashita
Saya Yamashita
KNKenta Noda
Kenta Noda
THTasuku Honjo
Tasuku Honjo
Current clinically approved biomarkers for the PD-1 blockade cancer immunotherapy are based entirely on the properties of tumour cells. With increasing awareness of clinical responses, more precise biomarkers for the efficacy are required based on immune properties. In particular, expression levels of immune checkpoint-associated molecules such as PD-1, PD-L1, and CTLA-4 would be critical to evaluate the immune state of individuals. Although quantification of their soluble form leased from the membrane will provide quick evaluation of patients’ immune status, available methods such as enzyme-linked immunosorbent assays to measure these soluble factors have limitations in sensitivity and reproducibility for clinical use. To overcome these problems, we developed a rapid and sensitive immunoassay system based on chemiluminescent magnetic technology. The system is fully automated, providing high reproducibility. Application of this system to plasma of patients with several types of tumours demonstrated that soluble PD-1, PD-L1, and CTLA-4 levels were increased compared to those of healthy controls and varied among tumour types. The sensitivity and detection range were sufficient for evaluating plasma concentrations before and after the surgical ablation of cancers. Therefore, our newly developed system shows potential for accurate detection of soluble PD-1, PD-L1, and CTLA-4 levels in the clinical practice.

1 May 2012 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
FNFumio Nomura
Fumio Nomura
KSKazuyuki Sogawa
Kazuyuki Sogawa
KNKenta Noda
Kenta Noda
MSMasanori Seimiya
Masanori Seimiya
Kazuyuki MatsushitaKazuyuki Matsushita
Kazuyuki Matsushita
OYOsamu Yokosuka
Osamu Yokosuka

9 February 2023 in European Journal of Cancer
Verified
Journal Article
Closed access
HKHisato Kawakami
Hisato Kawakami
Yu SunakawaYu Sunakawa
Yu Sunakawa
EIEisuke Inoue
Eisuke Inoue
RMRyo Matoba
Ryo Matoba
KNKenta Noda
Kenta Noda
MFMasashi Fujii
Masashi Fujii

23 November 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
SMShogo Minamikawa
Shogo Minamikawa
KNKandai Nozu
Kandai Nozu
SMShingo Maeta
Shingo Maeta
TYTomohiko Yamamura
Tomohiko Yamamura
KNKeita Nakanishi
Keita Nakanishi
KIKazumoto Iijima
Kazumoto Iijima
CD80, which regulates T cell activation, may provide a differential diagnostic marker between minimal change disease (MCD) and other renal diseases, including focal segmental glomerular sclerosis (FSGS). However, recent reports show contrasting results. Therefore, we evaluated the utility of urinary CD80 as a diagnostic biomarker. We collected 65 urine samples from 55 patients with MCD (n = 31), FSGS (n = 4), inherited nephrotic syndrome (n = 4), Alport syndrome (n = 5) and other glomerular diseases (n = 11), and control samples (n = 30). We measured urinary CD80 levels by ELISA. Urinary CD80 (ng/gCr) (median, interquartile range) levels were significantly higher in patients with MCD in relapse (91.5, 31.1–356.0), FSGS (376.2, 62.7–1916.0), and inherited nephrotic syndrome (220.1, 62.9–865.3), than in patients with MCD in remission (29.5, 21.7–52.8) (p < 0.05). Elevation of urinary CD80 was observed, even in patients with inherited nephrotic syndrome unrelated to T cell activation. Additionally, urinary CD80 was positively correlated with urinary protein levels. Our results suggest that urinary CD80 is unreliable as a differential diagnostic marker between MCD in relapse and FSGS or inherited kidney diseases. Increased urinary CD80 excretion was present in all patients with active kidney disease.